ASRS 2024: Social determinants of vision health in patients with rhegmatogenous retinal detachments
At this year's ASRS meeting, Sally S. Ong, MD, shared results from a 10-year study on socioeconomic barriers and visual outcomes
ASRS 2024: Examining 36-month outcomes of fluocinolone acetonide 0.18 with the CALM registry study
Ashkan Abbey, MD, discusses 36-month outcomes of real-world patients receiving fluocinolone acetonide 0.18 mg
ASRS 2024: A novel approach to myopic traction maculopathy
Nikoloz Labauri, MD, FVRS, speaks about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy at ASRS 2024
ASRS 2024: Aflibercept 8 mg and 2 mg, DME, and IOP outcomes in the phase 2/3 PHOTON trial
Jordana Fein, MD, MS, speaks about intraocular pressure outcomes in patients receiving aflibercept through week 48 of the PHOTON trial
ASRS 2024: Multiwavelength photobiomodulation significantly reduces risk for vision loss and onset of GA in dry AMD
Eleonora Lad, MD, PhD, discusses multiwavelength photobiomodulation significantly reduces risk for vision loss and onset of GA in dry AMD
ASRS 2024: Intraoperative fluorescein angiography reduces the rate of postoperative vitreous hemorrhage
Alan Franklin, MD, PhD, FASRS, a retina specialist in Mobile, Alabama spoke about his presentation, "Intraoperative Fluorescein Angiography Reduces the Rate of Postoperative Vitreous Hemorrhage."
ASRS 2024: Long-term results of macular hole surgery with long-acting gas tamponade
John Thompson, MD, discusses long-term results of using ICG to peel ILM in the treatment of macular holes
ASRS 2024: 100-week results from the RESTORE trial showcase retinitis pigmentosa outcomes
Michael Singer, MD, speaks at the American Society of Retina Specialists meeting
ASRS 2024: Diabetic retinopathy lesions and assessing disease severity over time
Paolo Antonio Silva, MD, discussed his upcoming ASRS presentation on diabetic retinopathy lesions
ASRS 2024: IOP outcomes following suprachoroidal triamcinolone acetonide use in non-infectious uveitis
Ahead of the ASRS meeting in Stockholm, Sweden, Danny Mammo, MD, discusses use of suprachoroidal triamcinolone acetonide in non-infectious uveitis
ASRS 2024: First-time results from a phase 1b study of FAS inhibition with ONL-1204
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204 for the treatment of geographic atrophy
ASRS 2024: Examining real-world use of faricimab through the FARETINA-DME Study
Theodore Leng, MD, MS, speaks about his ASRS presentation, focusing on the FARETINA-DME Study
ASRS 2024: Geographic atrophy findings from part 1 of the Phase 2/3 SIGLEC trial
Ahead of the ASRS meeting, Rishi P. Singh, MD, previews results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for geographic atrophy
ASRS 2024: Continuous treatment of DME with a port delivery system for ranibizumab
Carl C. Awh, MD, FASRS, gives an overview of the Phase 3 Pagoda trial year 2 results
ASRS 2024: 72-Week results from the Phase 3 BALATON and COMINO trials
Carl J. Danzig, MD, discusses efficacy, safety, and durability of faricimab in macular oedema due to retinal vein occlusion
ASRS 2024: Sustainability expert panel demonstrates how retina specialists go green
This year, the ASRS meeting will feature an expert panel on sustainability — learn more from panelist Martin Zinkernagel, MD, PhD
ASRS 2024: Geographic atrophy, lesion growth and outer retinal tubulation
Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal geographic atrophy
What are attendees most looking forward to at this year's ASRS meeting?
Four retina specialists share what they're most looking forward to at the 2024 ASRS meeting
ASRS 2024: Improving OCTA performance using AI and differential artery-vein analysis
Jennifer I. Lim, MD, FARVO, FASRS, discusses her ASRS presentation, "Differential Artery-Vein Analysis Improves OCTA Performance for Artificial Intelligence Classification of Diabetic Retinopathy"
ARVO 2024: Trial design and increased accuracy of meibomian gland morphology measurements
At the 2024 ARVO meeting, Andrew D. Pucker, OD, PhD, presented a paper on measuring meibomian gland morphology
ARVO 2024: Mutation agnostic optogenetic programme demonstrates possible treatment for patients with severe retinal degeneration
Allen Ho, MD, presented on the 12-month results of an mutation agnostic optogenetic programme at the ARVO 2024 meeting
ARVO 2024: Predicting the efficacy of myopia control methods using 1-year data
At this year's ARVO meeting, the Eye Care Network got a glimpse at the future of paediatric myopia control research
ARVO 2024: President-elect SriniVas Sadda, MD, shares his strategies for engaging vision experts worldwide
Incoming ARVO president SriniVas R. Sadda, MD, discussed major challenges in vision science research and how annual meetings inspire innovation in ophthalmology
ARVO 2024: Reliability of contact specular microscopy in the corneal endothelium
Elias Kahan speaks about his ARVO poster, "Contact specular microscopy reliably images the same location of the corneal epithelium"
ARVO 2024: Exploring multi-ingredient oral supplements for alleviating symptoms of dry eye disease
At this year's ARVO meeting, Neda Gioia, OD, discussed the increasing patient burden of dry eye disease
ARVO 2024: Evaluating a lipid-containing eye drop for dry eye disease
Eric Donnenfeld, MD, discusses the clinical evaluation of Blink Triple Care artificial tears ahead of the 2024 ARVO meeting
ARVO 2024: Dry eye patient selection following post-hoc analysis of GOBI and MOJAVE trials
John Sheppard, MD, MSc, FACs, discusses the unique biochemical traits of perfluorohexyloctane for eye dry disease and meibomian gland dysfunction
ARVO 2024: Assessing melanocortin receptors and inflammation in the ocular space
Paul Kayne, PhD gave an onsite overview of his poster at the 2024 ARVO meeting
ARVO 2024: Imaging provides insight into the metabolic aspects of glaucoma development
Osamah Saeedi, MD, MS, discusses his poster presentation from the ARVO Imaging in the Eye conference
ARVO 2024: Novel contact lens solution bolsters comfort in potential lens wear dropouts
Marjorie Rah, OD, PhD, FAAO, discussed the in-home use test of BioTrue Hydration Plus multipurpose contact lens solution (Bausch + Lomb) on patients who are considering lens dropout.